Try our Advanced Search for more refined results
Life Sciences
-
January 02, 2026
North Carolina Cases To Watch In 2026
In the new year, North Carolina state and federal courts are set to consider the intricacies of class action certification at the behest of thousands of fast-food workers and whether Chinese company TikTok Inc. is deliberately designing the app to addict children.
-
January 02, 2026
New Jersey Cases To Watch In 2026
In the coming year, New Jersey litigators will be watching for the outcome of an appeal in a constitutional challenge to school segregation and an employment discrimination case brought by a former Johnson & Johnson attorney.
-
January 02, 2026
SnapChat, Pork And Big Prosecutions: Trials To Watch In 2026
The coming year is set to bring high-profile trials, including in the criminal case against SCOTUSblog co-founder Tom Goldstein, as well as bellwether trials in multidistrict litigation concerning social media's effects on mental health and allegations of price-fixing in the generic-drug industry.
-
January 02, 2026
What To Watch In Massachusetts Courts In 2026
Massachusetts attorneys have their eye on Trump administration policy challenges, state ballot question disputes and False Claims Act enforcement shifts as the calendar turns to 2026.
-
January 02, 2026
Pennsylvania Cases To Watch In 2026
As winter's chill rings in the new year, several high-profile cases are set to heat up Pennsylvania's dockets in 2026, including disciplinary charges against a judge associated with rapper Meek Mill, a pending appeals decision on the lawfulness of semiautomatic rifles, and Philadelphia's quest to hold pharmacy benefit managers accountable for the opioid epidemic.
-
January 02, 2026
Patent Cases To Watch In 2026
The U.S. Supreme Court is considering whether to weigh in on generic-drug skinny labels, while the Federal Circuit is examining an effort by the U.S. Patent and Trademark Office to shield decisions from review. Here's a look at those cases and others that attorneys will be tracking in 2026.
-
January 02, 2026
The High-Stakes Healthcare AI Battles To Watch In 2026
Courts across the country are set to hear a wave of litigation in the coming year that will begin to draw the legal boundaries around artificial intelligence in healthcare and the life sciences. Law360 spoke with legal experts about the high-stakes AI litigation set to unfold in 2026.
-
January 01, 2026
4 High Court Cases To Watch This Spring
The U.S. Supreme Court justices will return from the winter holidays to tackle several constitutional disputes that range from who is entitled to birthright citizenship to whether transgender individuals are entitled to heightened levels of protection from discrimination.
-
January 01, 2026
Blue Slip Fight Looms Over Trump's 2026 Judicial Outlook
In 2025, President Donald Trump put 20 district and six circuit judges on the federal bench. In the year ahead, a fight over home state senators' ability to block district court picks could make it more difficult for him to match that record.
-
January 01, 2026
BigLaw Leaders Tackle Growth, AI, Remote Work In New Year
Rapid business growth, cultural changes caused by remote work and generative AI are creating challenges and opportunities for law firm leaders going into the New Year. Here, seven top firm leaders share what’s running through their minds as they lie awake at night.
-
December 24, 2025
Sanofi Buys Hepatitis Vaccine Maker Dynavax For $2.2B
French pharmaceutical giant Sanofi SA said Wednesday that it will buy Dynavax Technologies, a U.S. vaccine developer, for $2.2 billion in a recommended cash deal to expand its adult immunization products.
-
December 23, 2025
Top Illinois Decisions Of 2025
State and federal courts have handed down rulings in Illinois cases this year that made clear plaintiffs must allege concrete injury for common law standing, narrowed the scope of the federal anti-kickback statute and laid out a new standard for certifying collective actions.
-
December 23, 2025
3 Federal Circuit Clashes To Watch In January
The Federal Circuit is set to hear several intellectual property cases in January, including one over a nine-figure patent judgment against cybersecurity company Gen Digital tied to a contempt finding against a major law firm that represented it, and another over the tech industry's long-running crusade against patent review denials based on related litigation.
-
December 23, 2025
Philly Joins MDL Against Drug Cos., PBMs Over Insulin Prices
Philadelphia on Tuesday sued drug manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with several pharmacy benefit managers, joining multidistrict litigation in New Jersey federal court accusing the companies of illegally inflating the price of insulin.
-
December 23, 2025
Justices Urged To Spurn SG's Call To Tackle 'Skinny Labels'
Amarin Pharma Inc. on Tuesday urged the U.S. Supreme Court to reject the U.S. solicitor general's call to hear a patent case involving generic drug "skinny labels," saying the dispute over the company's heart drug Vascepa deals with factual issues not suitable for high court review.
-
December 23, 2025
AdaptHealth To Pay Investors $35M To End Inflated-Sales Suit
Medical device provider AdaptHealth Corp. has agreed to pay $35 million to settle a lawsuit accusing it of deceiving shareholders about its revenue projections as it "routinely engaged in improper and unethical tactics to inflate sales numbers."
-
December 23, 2025
Dem Sens. Blast Idea Of Charging Value-Based Patent Fees
A group of Democratic U.S. senators has asked Commerce Secretary Howard Lutnick not to move forward with a proposed overhaul of the U.S. patent fee system that reportedly would implement fees based on a patent's value, saying such changes would create a "prohibitive bar to innovation for start-ups and other small-to-mid-size businesses."
-
December 23, 2025
Squires Will Review If Hydrafacial's ITC Win Should End IPR
U.S. Patent and Trademark Office Director John Squires has paused the Patent Trial and Appeal Board's review of a Hydrafacial LLC skin treatment patent to consider the effect of a related U.S. International Trade Commission decision.
-
December 23, 2025
Federal Agencies Urge 9th Circ. To Lift Layoff Freeze
The U.S. government urged the Ninth Circuit to stay a court order barring agencies from laying off workers through next month under the shutdown deal, saying the court intruded on federal labor panels' territory and the funding resolution didn't bar layoffs agencies had in the works.
-
December 23, 2025
Blue Cross Seeks McDonald Hopkins' Fraud Warning Docs
Advice that McDonald Hopkins LLC gave a Florida hospital manager about potential exposure to criminal prosecution for healthcare fraud is neither privileged nor work product, and so should be handed over to a Blue Cross health insurer being sued for malicious prosecution in Georgia federal court, the insurer said.
-
December 23, 2025
Top New Jersey Cases Of 2025
New Jersey courts saw some history-making litigation come to a close over the course of 2025, including the largest environmental settlement ever achieved by a single state and the first clergy abuse trial verdict since the statute of limitations on child sexual abuse claims was extended. Another notable development was the state's federal bench exercising a rarely used authority to reject President Donald Trump's pick for interim U.S. attorney.
-
December 23, 2025
Sanofi Eczema Drug Linked To Lymphoma, Suit Says
Drug manufacturers Regeneron Pharmaceuticals and Sanofi were hit with a lawsuit Monday from a Georgia woman alleging the companies have covered up a "strong and consistent causal relationship" between their drug Dupixent and a form of non-Hodgkins lymphoma.
-
December 23, 2025
Baker Botts Hires 2 New DC Partners For Enviro, IP Team
Baker Botts LLP has hired two new partners in its intellectual property and environmental safety and incident response groups, who will both be based in the firm's Washington, D.C., office, Baker Botts said in recent announcements.
-
December 23, 2025
'Gas Station Heroin' Cos. Sued Over User's Overdose
The estate of a woman who died of a tianeptine overdose is suing the makers and sellers of tianeptine products in Pennsylvania state court, saying while they market the products as safe diet supplements, they're actually highly addictive opioids.
-
December 23, 2025
Johnson & Johnson Hit With $1.5B Talc Verdict In Baltimore
A Baltimore jury late Monday returned a walloping verdict of more than $1.5 billion in favor of a woman who claimed that Johnson & Johnson talc products caused her mesothelioma, which her attorneys say is the largest verdict against the company for a single plaintiff.
Expert Analysis
-
Adapting To A Plaintiff-Side Mindset For Patent Monetization
A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.
-
AI Evidence Rule Tweaks Encourage Judicial Guardrails
Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.
-
Series
The Law Firm Merger Diaries: Getting The Message Across
Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.
-
Opinion
Horizontal Stare Decisis Should Not Be Casually Discarded
Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.
-
10 Commandments For Agentic AI Tools In The Legal Industry
Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.
-
Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims
The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.
-
New Drug Ad Regs Could Lead To A Less Informed Public
A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.
-
Series
Preaching Makes Me A Better Lawyer
Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.
-
A Look At Middlemen Fees In 340B Drug Discount Program
A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.
-
How Large Patent Damages Awards Actually Play Out
Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.
-
Series
Law School's Missed Lessons: Practicing Client-Led Litigation
New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.
-
Navigating 2025's Post-Grant Proceeding Shakeups
Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.
-
Series
The Law Firm Merger Diaries: How To Build On Cultural Fit
Law firm mergers should start with people, then move to strategy: A two-level screening that puts finding a cultural fit at the pinnacle of the process can unearth shared values that are instrumental to deciding to move forward with a combination, says Matthew Madsen at Harrison.
-
Latisse Ruling's Lessons On Avoiding Chemical Patent Pitfalls
The Federal Circuit's decision in Duke v. Sandoz, reversing a $39 million infringement claim for selling a generic Latisse product, reinforces a fundamental truth in chemical patent strategy: Broad genus claims rarely survive without clear evidence of possession of specific embodiments, says Kimberly Vines at Stites & Harbison.
-
Considerations When Invoking The Common-Interest Privilege
To successfully leverage the common-interest doctrine in a multiparty transaction or complex litigation, practitioners should be able to demonstrate that the parties intended for it to apply, that an underlying privilege like attorney-client has attached, and guard against disclosures that could waive privilege and defeat its purpose, say attorneys at DLA Piper.